Dr. Ruchika Talwar

This week on the Backtable podcast.

Hi, everyone.

Welcome back to Backtable Urology.

Today, I'm really excited to be joined by Dr. Claire de la Calla, who's an assistant professor of urology at the University of Washington.

Claire, thanks for joining us.

I'm really excited to talk about active surveillance for intermediate-risk prostate cancer.

But first, why don't you tell the audience a little bit about yourself?

Yeah, you know, I think it's really, really relevant because it's becoming a common clinical scenario.

We've seen active surveillance evolve from a strategy that initially was reserved really exclusively for patients with low-risk prostate cancer.

But I'd argue that especially, you know, over time as we've been able to learn from your work and others out there who are looking at risk stratification and more accurate diagnostics, that I think, you know, it is a viable option for select patients who have

specifically favorable intermediate risk disease.

And we are seeing a lot of specialty organizations and guidelines actually include recommendations to consider active surveillance in those scenarios.

So as we're seeing this sort of paradigm shift, I think I would love to hear more from you about the current evidence that we have out there for active surveillance in patients who have intermediate risk disease.

Yeah, that's right.

And I think that brings me to my next question.

You're really well.

It's a nice tee up.

I wanted to cover a bit about what selection criteria can help us

better risk stratify patients within that intermediate category, whether someone is appropriate versus not.

But I think there's a lot to cover here.